Stock listing
NASDAQ:KARD Kardigan, Inc. Stock
Home listing (NASDAQ) of Kardigan, Inc.
Follow Kardigan, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:KARD
$11.54 USD -0.78 (-6.3%)
Close on Nov 20, 2026
- Day range
- $11.49 – $12.77 USDNov 20, 2026
- Volume
- 459,243 sharesNov 20, 2026
- Market cap
- $1.08B USDAt the close on Nov 20, 2026 · price × 93.60M shares outstanding
- Traded on an average day
- $9.47M USDMedian day 462,303 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KARD · Home | $11.54 USD | -0.78 (-6.3%) | 459,243 | $12.09 | $12.77 | $11.49 | $12.32 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KARD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $11.54 | -0.78 | -6.3% | $12.09 | $12.77 | $11.49 | 459,243 | |
| $12.32 | -0.87 | -6.6% | $13.19 | $13.51 | $12.25 | 546,424 | |
| $13.19 | +0.34 | +2.6% | $12.87 | $13.46 | $12.65 | 356,746 | |
| $12.85 | -0.97 | -7.0% | $13.63 | $13.63 | $12.68 | 395,703 | |
| $13.82 | -0.30 | -2.1% | $13.91 | $14.36 | $12.77 | 410,885 | |
| $14.12 | -1.56 | -9.9% | $15.42 | $15.85 | $14.11 | 345,772 | |
| $15.68 | +0.50 | +3.3% | $15.35 | $16.12 | $15.02 | 432,177 | |
| $15.18 | 0.00 | 0.0% | $15.30 | $15.94 | $14.93 | 769,733 | |
| $15.18 | -0.34 | -2.2% | $15.50 | $16.59 | $15.11 | 421,132 | |
| $15.52 | +1.66 | +12.0% | $14.00 | $15.56 | $13.57 | 406,389 | |
| $13.86 | -1.70 | -10.9% | $15.65 | $15.79 | $13.74 | 675,632 | |
| $15.56 | +1.24 | +8.7% | $15.24 | $15.59 | $14.40 | 491,053 | |
| $14.32 | +0.11 | +0.8% | $14.23 | $15.19 | $13.97 | 545,033 | |
| $14.21 | +0.08 | +0.6% | $14.34 | $14.69 | $13.53 | 462,303 | |
| $14.13 | -0.18 | -1.3% | $14.25 | $14.65 | $13.75 | 452,669 | |
| $14.31 | +0.58 | +4.2% | $14.07 | $14.94 | $14.07 | 446,299 | |
| $13.73 | +0.13 | +1.0% | $13.60 | $13.83 | $13.21 | 469,173 | |
| $13.60 | +0.97 | +7.7% | $12.65 | $13.71 | $12.43 | 452,701 | |
| $12.63 | -0.17 | -1.3% | $12.84 | $13.15 | $12.60 | 216,096 | |
| $12.80 | +0.06 | +0.5% | $12.66 | $12.87 | $12.34 | 679,813 | |
| $12.74 | -0.11 | -0.9% | $12.86 | $13.05 | $12.40 | 380,890 | |
| $12.85 | -0.66 | -4.9% | $13.59 | $14.01 | $12.68 | 480,734 | |
| $13.51 | +0.57 | +4.4% | $13.06 | $13.70 | $12.74 | 768,714 | |
| $12.94 | -0.09 | -0.7% | $13.04 | $13.73 | $12.76 | 622,072 | |
| $13.03 | -0.85 | -6.1% | $13.95 | $14.51 | $12.75 | 717,600 | |
| $13.88 | +0.36 | +2.7% | $13.80 | $14.13 | $13.13 | 660,900 | |
| $13.52 | +0.55 | +4.2% | $12.53 | $13.61 | $12.34 | 826,700 | |
| $12.97 | -1.38 | -9.6% | $14.36 | $14.61 | $12.93 | 392,600 | |
| $14.35 | -0.32 | -2.2% | $14.69 | $15.10 | $14.21 | 256,800 | |
| $14.67 | +0.47 | +3.3% | $14.44 | $15.93 | $14.13 | 740,200 | |
| $14.20 | +0.37 | +2.7% | $13.60 | $14.47 | $13.42 | 511,800 | |
| $13.83 | +0.34 | +2.5% | $13.34 | $14.19 | $12.23 | 1,025,700 | |
| $13.49 | -1.75 | -11.5% | $15.25 | $15.25 | $12.52 | 1,560,900 | |
| $15.24 | +0.45 | +3.0% | $14.77 | $15.40 | $14.35 | 380,900 | |
| $14.79 | +0.54 | +3.8% | $14.48 | $15.27 | $14.15 | 524,400 | |
| $14.25 | -0.50 | -3.4% | $14.65 | $15.13 | $13.94 | 913,900 | |
| $14.75 | +0.09 | +0.6% | $14.81 | $14.87 | $14.16 | 487,800 | |
| $14.66 | -0.12 | -0.8% | $14.75 | $15.06 | $14.33 | 493,600 | |
| $14.78 | -0.01 | -0.1% | $14.59 | $15.25 | $14.59 | 364,900 | |
| $14.79 | +0.40 | +2.8% | $14.69 | $15.60 | $14.07 | 628,900 | |
| $14.39 | -0.13 | -0.9% | $14.54 | $14.54 | $13.75 | 862,400 | |
| $14.52 | -1.92 | -11.7% | $16.50 | $16.50 | $14.24 | 653,800 | |
| $16.44 | +0.14 | +0.9% | $16.55 | $16.58 | $16.08 | 598,200 | |
| $16.30 | -0.34 | -2.0% | $16.86 | $18.28 | $16.13 | 724,500 | |
| $16.64 | -0.05 | -0.3% | $16.69 | $17.00 | $15.86 | 6,566,500 | |
| $16.69 | -0.62 | -3.6% | $17.45 | $18.48 | $16.50 | 710,200 | |
| $17.31 | -1.25 | -6.7% | $18.49 | $19.01 | $17.15 | 986,900 | |
| $18.56 | -0.49 | -2.6% | $18.95 | $19.07 | $18.32 | 344,900 | |
| $19.05 | +0.53 | +2.9% | $18.59 | $19.39 | $17.77 | 806,600 | |
| $18.52 | -0.17 | -0.9% | $19.01 | $19.81 | $18.41 | 416,400 | |
| $18.69 | -0.99 | -5.0% | $19.85 | $20.04 | $18.69 | 433,100 | |
| $19.68 | -1.92 | -8.9% | $21.44 | $22.00 | $19.62 | 382,900 | |
| $21.60 | +0.75 | +3.6% | $21.06 | $22.05 | $20.77 | 538,100 | |
| $20.85 | +0.11 | +0.5% | $20.50 | $21.41 | $20.50 | 279,600 | |
| $20.74 | -1.18 | -5.4% | $21.96 | $22.22 | $20.41 | 262,800 | |
| $21.92 | +2.32 | +11.8% | $19.80 | $22.51 | $19.74 | 354,900 | |
| $19.60 | -0.56 | -2.8% | $20.05 | $20.40 | $19.41 | 327,000 | |
| $20.16 | +0.14 | +0.7% | $20.02 | $20.72 | $20.00 | 184,900 | |
| $20.02 | -0.78 | -3.8% | $20.61 | $20.93 | $19.99 | 196,600 | |
| $20.80 | -0.38 | -1.8% | $21.12 | $21.90 | $20.33 | 546,600 | |
| $21.18 | +0.26 | +1.2% | $20.92 | $21.47 | $20.50 | 214,300 | |
| $20.92 | +0.28 | +1.4% | $20.75 | $21.38 | $20.51 | 229,955 | |
| $20.64 | -0.38 | -1.8% | $21.04 | $21.65 | $20.25 | 281,391 | |
| $21.02 | +0.76 | +3.8% | $20.47 | $21.76 | $20.46 | 159,600 | |
| $20.26 | -1.75 | -8.0% | $21.91 | $22.16 | $20.01 | 258,400 |
- Ticker
- NASDAQ:KARD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 35 slides
Latest news
Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates
Nov 12, 2026
Closed $14.12 (-9.9%) on Nov 12, 2026
Kardigan to Participate in the Jefferies Global Healthcare Conference
Nov 11, 2026
Closed $15.68 (+3.3%) on Nov 11, 2026
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
Nov 6, 2026
Closed $15.18 (-2.2%) on Nov 9, 2026
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
Sep 30, 2026
Closed $14.75 (+0.6%) on Sep 30, 2026
Kardigan to Present at Two September Investor Conferences
Sep 2, 2026
Closed $20.74 (-5.4%) on Sep 3, 2026
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Aug 11, 2026
Closed $22.06 (+4.6%) on Aug 11, 2026
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Jun 22, 2026
Closed $22.24 (-2.3%) on Jun 23, 2026
Kardigan, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 7 in the last 12 months · 7 in all · newest Nov 12, 2026 · oldest 2026
- Decks
- 1 deck · latest September 2026
Where Kardigan, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KARD · Home listing · This page | NASDAQ | United States | USD |
| BOATS:KARD | BOATS | United States | USD |
Valuation
Price/book 1.9× against a median of 6.1×: 2nd lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $621.1M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kardigan, Inc. · NASDAQ:KARD | US$1.08B | US$621.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| COMPASS Pathways Plc · NASDAQ:CMPS | US$1.14B | US$747.8M | n/a | n/a | n/a | 8.0× | n/a | 0.4× | 1.65 |
| Ascentage Pharma Group International · HKEX:6855 | US$1.11B | US$1.14B | n/a | 13.7× | n/a | 13.4× | −216.5% | 3.8× | n/a |
| Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321 | US$1.10B | US$1.10B | 102× | 6.8× | n/a | 2.9× | 6.6% | 0.5× | n/a |
| Pharma Mar SA · BME:PHM | US$1.10B | US$978.5M | 14.6× | 3.8× | 16.6× | 4.2× | 28.8% | 0.3× | n/a |
| Alpha Tau Medical Ltd · NASDAQ:DRTS | US$1.09B | US$1.00B | n/a | n/a | n/a | 55.3× | n/a | 0.8× | 1.89 |
| PYC Therapeutics Limited · ASX:PYC | US$1.07B | US$775.8M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Jade Biosciences, Inc. · NASDAQ:JBIO | US$1.06B | US$583.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.14 |
| MedinCell SA · EURONEXT:MEDCL | US$1.05B | US$1.02B | n/a | 38.4× | n/a | 313× | −128.9% | 18.7× | n/a |
| Nektar Therapeutics · NASDAQ:NKTR | US$1.03B | US$492.8M | n/a | 9.4× | n/a | 1.2× | −339.7% | 0.1× | 1.28 |
| Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062 | US$1.02B | US$984.8M | n/a | 9.2× | n/a | 9.5× | −146.4% | 2.9× | n/a |
| Median of the others | US$1.08B | US$981.7M | 58.5× | 9.3× | 16.6× | 6.1× | −137.6% | 0.4× | 1.47 |
Forecasts
8 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 41.13 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.29 · 6 analysts
- Revenue, year to Dec 2026
- 250K · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Tassos Gianakakos | Co-Founder, Chief Executive Officer and Chair |
| Brianne Puglisi | Chief Financial Officer |
| John Moriarty | Chief Legal Officer and Corporate Secretary |
| Michael Bachner | Executive Director, Corporate Communications |
| Andy Pasternak | Chief Strategy Officer |
| Bob McDowell | Co-Founder and Scientific Adviser |
| Diane Hagerty | Chief Quality Officer |
| Donald Mackenzie | Chief Technical Operations Officer |
| Emily Faucette | Chief Communications Officer |
| Jay Edelberg | Co-founder and Chief Medical Officer |
| Liz Nguyen | Chief People Officer |
Board
| Director | Role |
|---|---|
| Tassos Gianakakos | Co-Founder, Chief Executive Officer and Chair |
| David Meeker | Board of Directors |
| Kim Popovits | Board of Directors |
| Kristin Reinke | Board of Directors |
| Michael Bachner | Executive Director, Corporate Communications |
| Paul Berns | Board of Directors |
| Tim Walbert | Board of Directors |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −9.9% |
| Q2 2026 | Aug 11, 2026 · Before open | +4.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 35 slides | September 2026 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$460M raised · US$16 a share · J.P. Morgan Securities LLC +3 Dealers: J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, TD Securities (USA) LLC | Jun 22, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Jun 17, 2026.
- Price
- US$16.00 a share
- Shares offered
- 25,000,000 shares of common stock
- Offering size
- US$400 million
- Underwriters' option
- Up to 3,750,000 more shares
- Listing
- KARD on the Nasdaq Global Market
- Underwriters
- J.P. Morgan, Jefferies, Leerink Partners, TD Cowen · In the order on the cover
- Shares delivered
- On or about Jun 22, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 26, 2026 |
| Filed publicly | May 26, 2026 |
| Amended once | Jun 11, 2026 |
| Shares registered with an exchange | Jun 15, 2026 |
| Declared effective by the SEC | Jun 17, 2026 |
| Final prospectus, with the price | Jun 18, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 18, 2026 |
| EFFECT · Notice that a registration is effective | Jun 17, 2026 |
| S-1MEF · Registration of more shares for the same offering | Jun 17, 2026 |
| CERT · Exchange's certificate of listing | Jun 17, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 15, 2026 |
| S-1/A · Registration statement, amended | Jun 11, 2026 |
| S-1 · Registration statement | May 26, 2026 |
| DRS/A · Draft registration statement, amended | May 4, 2026 |
| DRS · Draft registration statement | Mar 26, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 18, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development | 153.1M | 84.3M |
| Selling, general and administrative | 48.8M | 12.4M |
| Operating income | -201.8M | -96.7M |
| Depreciation and amortization | 5.85M | 346.0K |
| EBITDA | -196.0M | -96.3M |
| Income before tax | -196.5M | -88.7M |
| Income tax | -4.51M | |
| Net income | -191.9M | -88.7M |
| Earnings per share, basic | -3.20 | -0.99 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 109.0M | 49.4M |
| Short-term investments | 226.5M | 0 |
| Current assets | 345.4M | 50.3M |
| Total assets | 390.9M | 63.5M |
| Accounts payable | 7.99M | 3.86M |
| Current liabilities | 37.5M | 8.29M |
| Total debt | 13.8M | |
| Total liabilities | 641.3M | 146.7M |
| Shareholders' equity | -250.3M | -83.2M |
| Shares outstanding | 60.0M | 89.3M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -151.1M | -18.8M |
| Capital spending | -6.64M | -36.4M |
| Free cash flow | -157.7M | -55.2M |
| Cash from investing | -237.0M | |
| Cash from financing | 447.8M | 105.0M |
| Change in cash | 59.7M | 49.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 1, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 1, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 30, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
All 57 filings
Cap table
Built by 6ix from Kardigan, Inc.’s releases · as of Nov 9, 2026
- Common shares
- 93,597,398
- Fully diluted
- 93,597,398
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 93,597,398 | Nov 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 93,597,398 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Timothy P. Walbert Other companies: Latigo Biotherapeutics, Inc. (Chair, Board of Directors · Since at least Aug 6, 2026); Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 24, 2025); Sagimet Biosciences Inc. - Series A (Director · Since at least Apr 1, 2024); Mirum Pharmaceuticals, Inc. (Director · Since at least Apr 5, 2023); Century Therapeutics, Inc. (Director · Since at least Oct 1, 2022); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2022 · Past); Assertio Holdings, Inc. (Director · May 20, 2020 – May 20, 2020 · Past); Exicure, Inc. (Director · Jul 22, 2019 – Jun 2, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Oct 12, 2015 – Feb 13, 2018 · Past); Egalet Corporation (Director · Mar 10, 2014 – May 20, 2020 · Past); Horizon Pharma PLC (Chairman, President and CEO, Director · Jul 28, 2011 – Mar 23, 2019 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Mar 13, 2014 · Past); Idm Pharma Inc (President and CEO, Director · May 25, 2007 – Apr 3, 2008 · Past) | Board of Directors · Since at least Jun 17, 2026 |
| Kristina Burow Other companies: Metsera, Inc. (Director · Since at least Jan 30, 2025); Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Scholar Rock Holding Corporation (Director · Since at least May 23, 2018); Metacrine Inc (Director · Sep 15, 2020 – May 24, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Jun 6, 2023 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 21, 2020 · Past); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Receptos Inc (Director · Aug 25, 2015 – Aug 25, 2015 · Past) | Director · Since at least Jun 22, 2026 |
| Keith Crandell Other companies: Metsera, Inc. (Director · Since at least Nov 13, 2025); 908 Devices Inc. (Director · Since at least Dec 17, 2020); Twist Bioscience Corporation (Co-Founder and Managing Director · Since at least Oct 30, 2018); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Quanterix Corporation (Director · Dec 6, 2017 – Apr 3, 2023 · Past); Adesto Technologies Corporation (Director · Oct 26, 2015 – Jun 4, 2019 · Past); Celebrate Express Inc (Director · Oct 19, 2006 – Aug 29, 2008 · Past) | Director · Since at least Jun 22, 2026 |
| Kimberly Popovits Other companies: Rhythm Pharmaceuticals, Inc. (Director · Since at least Apr 1, 2026); EXACT Sciences Corporation (Director · Since at least Jan 2, 2025); 10x Genomics, Inc. (Director · Since at least Mar 26, 2020); Kiniksa Pharmaceuticals International, plc (Director · Since at least May 23, 2018); Talis Biomedical Corp (Director · Feb 11, 2021 – Jun 9, 2023 · Past); MyoKardia Inc (Director · Mar 15, 2017 – Nov 17, 2020 · Past); Genomic Health Inc (President and CEO, Director · Nov 3, 2016 – Nov 8, 2019 · Past) | Director · Since at least Jun 17, 2026 |
| David Meeker Other companies: Pharvaris N.V. (Chair of the Board · Since at least Mar 18, 2026); Trevi Therapeutics, Inc. (Chairman · Since at least May 7, 2019); Rhythm Pharmaceuticals, Inc. (Chairman, President, and Chief Executive Officer · Since at least Oct 4, 2017); Turmeric Acquisition Corp (Director · Oct 15, 2020 – Oct 15, 2020 · Past); MyoKardia Inc (Director · Apr 17, 2017 – Nov 17, 2020 · Past); Savient Pharmaceuticals Inc (Director · Jan 7, 2013 – Jan 7, 2013 · Past) | Board of Directors · Since at least Jun 17, 2026 |
| Steven Gillis Other companies: Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 16, 2023 · Past); VBI Vaccines Inc. (Director · Jun 14, 2019 – Jul 27, 2023 · Past); Q32 Bio Inc. (Director · Jun 6, 2019 – Jun 14, 2023 · Past); Pulmatrix, Inc. (Director · May 16, 2019 – Aug 28, 2020 · Past) | Director · Since at least Jun 22, 2026 |
| Paul L. Berns Other companies: Metsera, Inc. (Director · Since at least Jan 30, 2025); Neumora Therapeutics, Inc. (See Remarks, Director · Since at least Sep 14, 2023); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Unity Biotechnology Inc (Director · Jun 24, 2021 – Jun 21, 2024 · Past); Jazz Pharmaceuticals plc (Director · Nov 2, 2020 – Aug 5, 2021 · Past) | Director · Since at least Jun 17, 2026 |
| John Moriarty Other companies: Avidity Biosciences, Inc (Chief Legal Officer · Since at least Aug 1, 2024); Olema Pharmaceuticals, Inc. (EVP, Ch. Legal Officer & Sec. · Sep 19, 2020 – Feb 1, 2023 · Past); Portola Pharmaceuticals Inc (EVP, General Counsel · Mar 12, 2018 – Jul 2, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & General Counsel · Dec 10, 2012 – Feb 6, 2018 · Past) | Chief Legal Officer and Corporate Secretary · Since at least Jun 17, 2026 |
| Bob McDowell Other companies: MyoKardia Inc (Chief Scientific Officer · Oct 28, 2015 – Nov 17, 2020 · Past); Sunesis Pharmaceuticals Inc (Vice President, Research · Sep 11, 2007 – Sep 13, 2007 · Past) | Co-Founder and Scientific Adviser · Since at least Nov 5, 2026 |
| Anastasios Gianakakos Other companies: MyoKardia Inc (President and CEO, Director · Oct 28, 2015 – Nov 17, 2020 · Past) | President & CEO, Director · Since at least Jun 17, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Douglas E Giordano Other companies: Cerevel Therapeutics Holdings Inc (Director · Jun 14, 2022 – Aug 1, 2024 · Past) | Director · Since at least Jun 17, 2026 |
| Joseph Edelman Other companies: Immatics N.V. (Director · Since at least Aug 26, 2026) | Director · Since at least Jun 17, 2026 |
| Kim Popovits Other companies: 10x Genomics, Inc. (Member · Since at least Jun 8, 2026) | Board of Directors · Since at least Jun 22, 2026 |
| Robert Nelsen Other companies: City Therapeutics, Inc. (Director · Since at least Oct 19, 2026) | Director · Since at least Jun 22, 2026 |
| Andy Pasternak | Chief Strategy Officer · Since at least Jun 22, 2026 |
| Brianne Jahn | Chief Financial Officer · Since at least Jun 17, 2026 |
| Brianne Puglisi | Chief Financial Officer · Since at least Nov 5, 2026 |
| Diane Hagerty | Chief Quality Officer · Since at least Nov 5, 2026 |
| Donald Mackenzie | Chief Technical Operations Officer · Since at least Nov 5, 2026 |
| Emily Faucette | Chief Communications Officer · Since at least Nov 5, 2026 |
| Jay Edelberg | Co-founder and Chief Medical Officer · Since at least Jun 17, 2026 |
| Kristin Reinke | Board of Directors · Since at least Sep 30, 2026 |
| Liz Nguyen | Chief People Officer · Since at least Nov 4, 2026 |
| Michael Bachner | Executive Director, Corporate Communications · Since at least Aug 11, 2026 |
| Tassos Gianakakos | Co-Founder, Chief Executive Officer and Chair · Since at least Sep 30, 2026 |
Log in to ask 6ix AI your own questions about Kardigan, Inc.